3D Prediction of Patient-Specific Response

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

570 participants

Study Classification

OBSERVATIONAL

Study Start Date

2018-06-11

Study Completion Date

2024-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a prospective, non-randomized, observational registry study evaluating a patient-specific ex vivo 3D (EV3D) assay for drug response using a patient's own biopsy or resected tumor tissue for assessing tissue response to therapy in patients with advanced cancers, including ovarian cancer, high-grade gliomas, and high-grade rare tumors.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Study to Evaluate the Safety and Efficacy of NKTR-102 in Patients With Metastatic or Locally Advanced Ovarian Cancer

NCT00806156

Tumor Ovarian Cancer

COMPLETED PHASE2

Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

NCT02839707

Fallopian Tube High Grade Serous Adenocarcinoma Ovarian High Grade Serous Adenocarcinoma Ovarian Seromucinous Carcinoma +16 more

ACTIVE_NOT_RECRUITING PHASE2/PHASE3

Safety and Pharmacokinetics of DMUC5754A Administered Intravenously to Patients With Platinum-Resistant Ovarian Cancer or Unresectable Pancreatic Cancer

NCT01335958

Ovarian Cancer, Pancreatic Cancer

COMPLETED PHASE1

A Study of Targeted Agents for Patients With Recurrent or Persistent Endometrial Cancer

NCT04486352

Endometrial Cancer

RECRUITING PHASE1/PHASE2

Liposomal Doxorubicin in Treating Patients With Advanced or Recurrent Endometrial Cancer

NCT00005861

Endometrial Cancer

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This protocol defines a prospective, open-label, multi-institutional, non-interventional study for the purpose of examining the Assay's clinical use and potential to impact patient outcomes. This Study will establish a registry of clinical parameters, including clinical response, clinical outcomes, Assay performance and potential utilization across multiple types of advanced cancers in consenting patients who have their tumor tissue tested by the Assay. Physicians may have access to Assay results which which predict therapeutic response to cancer drugs most often prescribed to treat the specified indications. For cancers with standard of care (SOC) cancer drug treatments, the Assay panel tests SOC systemic agents per NCCN guidelines, some of which may include both FDA approved and off-label FDA approved therapies. The Assay currently assesses the most common cancer drugs across multiple tumor types. It requires freshly obtained tumor specimen that has not been previously preserved for traditional histologic analysis. The Registry will focus initially on tumor types and agents which have been analytically validated with the Assay and determined to meet strict laboratory qualifications and standards. The Registry will collect data on a limited number of cancer types to include epithelial ovarian cancer (EOC), high-grade gliomas (HGG) limited to anaplastic astrocytoma (AA) and glioblastoma multiforme (GBM), and high-grade rare tumors (RT).

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Advanced Cancer Ovarian Cancer Glioblastoma Multiforme Anaplastic Astrocytoma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Tumor tissue tested with EV3D Assay

Cancer tissue from multiple sites in the body, to include ovarian, brain, and other rare tumors.

EV3D Assay

Intervention Type DIAGNOSTIC_TEST

The EV3D assay uses freshly obtained tumor specimen to predict tissue drug response.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

EV3D Assay

The EV3D assay uses freshly obtained tumor specimen to predict tissue drug response.

Intervention Type DIAGNOSTIC_TEST

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age 18 years and older
* Diagnosis of or suspected diagnosis of EOC, HGG, high-grade RT
* Individual must undergo elective surgery or biopsy to remove tumor tissue
* Consideration as a candidate for systemic therapy with cytotoxic chemotherapy, targeted small molecule inhibitors or immunotherapy
* Eastern Cooperative Oncology Group (ECOG) Performance Status ≤ 3
* Written informed consent in accordance with institutional standards must be obtained from the patient or legal guardian

Exclusion Criteria

* Inability or refusal of the patient or legal guardian to sign a written informed consent
* Failure to have surgery or a biopsy as part of routine clinical practice
* Refusal to have the Assay performed on their tissue
* Known active cancer metastatic to the brain except for patients with brain metastases that have been treated and are considered stable.
* Inability or unwillingness to receive chemotherapy treatment beyond surgery
* Any coincidental medical condition that, in the Investigator's opinion, would preclude participation in the study or compromise the patient's ability to give informed consent

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No